Dataset Information

Temporal phosphoproteomic analysis of VEGF-A signaling in HUVECs: An insight into early signaling events associated with angiogenesis

ABSTRACT: Aim of the study was to elucidate the phosphoproteomics alterations caused by the treatment of VEGF-A in HUVEC cells at early timepoints of 1, 5 and 10 minutes. Label-free quantitative temporal phosphoproteomics experiments were carried out using LC-MS/MS methods. LTQ orbitrap XL ETD (Thermo Electron, San Jose, CA, USA) connected to UltiMate 3000 nanoLC Pump (Dionex Co., Sunnyvale, CA, USA) was used for data acquisition.

INSTRUMENT(S): LTQ Orbitrap Elite

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Placenta, Huvec Cell

SUBMITTER: Abhinand C S

LAB HEAD: Abhinand S. Chandran

PROVIDER: PXD038133 | Pride | 2023-10-24

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	180323acs_001_HUVEC_P5_no_VEGF_control_1_001.RAW	Raw
	180323acs_002_HUVEC_P5_no_VEGF_control_1_002.RAW	Raw
	180323acs_003_HUVEC_P5_50ng_mL_VEGF_1min_1_001.RAW	Raw
	180323acs_004_HUVEC_P5_50ng_mL_VEGF_1min_1_002.RAW	Raw
	180323acs_005_HUVEC_P5_50ng_mL_VEGF_5min_1_001.RAW	Raw

Items per page:

1 - 5 of 27

Publications

Temporal phosphoproteomic analysis of VEGF-A signaling in HUVECs: an insight into early signaling events associated with angiogenesis.

Abhinand Chandran S CS Galipon Josephine J Mori Masaru M Ramesh Poornima P Prasad Thottethodi Subrahmanya Keshava TSK Raju Rajesh R Sudhakaran Perumana R PR Tomita Masaru M

Journal of cell communication and signaling 20230307 3

Vascular endothelial growth factor-A (VEGF-A) is one of the primary factors promoting angiogenesis in endothelial cells. Although defects in VEGF-A signaling are linked to diverse pathophysiological conditions, the early phosphorylation-dependent signaling events pertinent to VEGF-A signaling remain poorly defined. Hence, a temporal quantitative phosphoproteomic analysis was performed in human umbilical vein endothelial cells (HUVECs) treated with VEGF-A-165 for 1, 5 and 10 min. This led to the ...[more]

PMID: 36881336

Similar Datasets

Project description:Purpose: By integrating DNA methylation and gene expression of COPD lung tissues, we identified EPAS1 as a key regulator whose downstream genes significantly overlapped with multiple genes sets associated with COPD disease severity. EPAS1 is distinct in comparison with other key regulators in terms of methylation profiles and downstream target genes. Genes predicted to be regulated by EPAS1 were enriched for biological processes including signaling, cell communications, and system developement. As EPAS1 downstream genes were significantly enriched for hypoxia responsive genes in endothelial cells, we tested EPAS1 function in human and mouse endothelial cells HUVEC and C166. EPAS1 knockdown by siRNA in endothelial cells impacted genes that significantly overlapped with EPAS1 downstream genes in lung tissue including hypoxia responsive genes. Methods: The cell lines of HUVEC (Lonza, MD, USA) and C166 (American Type Culture Collection, VA, USA) were cultured in the appropriate media at 37M-BM-0C with 5% CO2. The cells were transfected with EPAS1 siRNA and non-targeting negative control siRNA (Life Technologies, CA, USA) using Lipofectamine RNAiMAX as recommended transfection protocols by the manufacturer. After the treatments with 5nM SilencerM-BM-. Select siRNA (s4700 for EPAS1, s65525 for Epas1; Life Technologies, USA) for 48 hours, the total RNA was purified with RNeasy Mini Kit (QIAGEN, Germany). The efficiencies of knocked down the EPAS1 expression were assessed by qPCR with 1.4% for HUVEC, 3.2% for C166. Approximately 250 ng of total RNA per sample were used for library construction by the TruSeq RNA Sample Prep Kit (Illumina) and sequenced using the Illumina HiSeq 2500 instrument with 100nt single read setting according to the manufacturer's instructions. Sequence reads were aligned to human genome assembly hg19 and mouse genome assembly mm10, respectively, using Tophat [96]. Total 23,228 human and 22,609 mouse genes were quantified using Cufflinks [96]. siRNA signatures were derived by comparing expression profiles of EPAS1 or Epas1 siRNAs with non-targeting siRNAs at paired t-test p-value cutoff 0.05 with resulting signature sizes of 2,796 and 3,730, and corresponding q-values [97] 0.11 and 0.07 for HUVEC and C166, respectively. Results: When comparing endothelial cells treated with EPAS1 siRNAs and scrambled siRNAs, we identified an EPAS1 siRNA signature consisting of 2796 and 3730 genes in human and mouse endothelial cell lines, respectively, whose expression levels significantly changed (t-test p-value<0.05), including EPAS1 itself (p-value = 0.002 and 0.02) and the EPAS1 downstream target gene VEGFA (p-value = 0.03 and 0.01). The EPAS1 siRNA signatures derived from human and mouse cell lines were highly consistent, with 695 genes in common to both signatures (p-value = 7.2x10-65). Both signatures not only significantly overlapped with EPAS1 downstream genes (p-value = 7.3x10-7 and 1.5x10-12), but also with hypoxia response genes in endothelial cells (FisherM-bM-^@M-^Ys Exact Test p-value = 5.8x10-8 and 1.2x10-12 in the human and mouse signatures, respectively). Moreover, the EPAS1 siRNA signatures consistently overlapped genes associated with the COPD severity phenotypes. These results together validate that EPAS1 causally regulates the downstream target genes we predicted, and that these genes in turn affect COPD development and progression. For each of human and mouse cell lines, 3 siRNA control cells, and 3 siRNA EPAS1 knockdown cells were used and analyzed. To identify EPAS1 signatures, paired t-test was performed between control siRNA and EPAS1 siRNA samples.

Project description:In this study we used the cre-loxP recombinase system. All mice were genetically modified in as much as all mice had exon 4 of the IGF-I gene flanked by loxP sites. In the knockouts, Mx-Cre had also been introduced, which results in inactivation of the IGF-I gene specifically in the liver. RNA from liver, skeletal muscle, heart, fat (retroperitoneal fat) and bone (vertebrae) was extracted from 6 control and 7 mice deficient of liver-derived insulin-like growth factor-I (LI-IGF-I-/- mice) by Tri Reagent (Sigma, St. Louis, MO, USA) and purified using spin columns from Rneasy Total RNA Isolation Kit (Qiagen, Chatsworth, CA, USA). For microarray analysis, the RNA samples were pooled three or two, resulting in three pools per group while for the confirmatory RT-PCR analyses individual mice (n=6-7) were analyzed. For each organ, there were three pooled samples from the mice with deficiency of liver-derived IGF-I and 3 pooled samples from the wildtype mice i.e. intact IGF-I gene. The pooled RNA was reverse transcribed into cDNA, labeled, and analyzed by DNA microarray (MG-U74Av2 Array; Affymetrix, Santa Clara, CA, USA). Scanned output files were analyzed using Affymetrix Micro Array Suite version 4.0.1 software (Affymetrix). To allow comparison of gene expression, the gene chips were globally scaled to an average intensity of 500. Each of the three LI-IGF-I-/- chips was compared with the three control chips, generating a total of nine comparison files. Only the genes that were regarded as M-^SchangedM-^T according to the Affymetrix algorithm in four to nine of the comparisons were selected for further analysis. We then calculated an average-fold change for the nine comparisons of the selected genes. For a gene to be regarded as consistently regulated in the LI-IGF-I-/- mice, the average-fold increase or decrease of the nine comparisons was set as at least 1.5 fold in at least 4 of the 5 analyzed organs. Microarray showed that heat shock protein 1A (Hspa1a), heat shock protein 1B (Hspa1b), and connective tissue growth factor (Ctgf) were decreased in all organs that expressed these genes. CCAAT/enhancer protein delta (Cebpd) decreased in 4 of the 5 analyzed organs. The RT-PCR analyses that were performed later confirmed that mRNA levels of Hspa1a, Hspa1b, and Ctgf decreased in LI-IGF-I-/- mice in skeletal muscle tissue while mRNA levels of Cebpd were unchanged.